Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Faster MRI could replace CT scans for liver cancer survivors

NCT ID NCT06537193

Diagnosis Sponsor: Asan Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a shorter, contrast-enhanced MRI scan can detect liver cancer recurrence as well as standard CT scans in people who have been cancer-free for over two years after treatment. About 455 participants will receive both scans to compare their accuracy. The goal is to find a safer screening method that reduces radiation and contrast agent risks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
gadoxetic acid (Primovist)
What this could lead to
If successful, this could lead to a safer, faster, and equally effective way to monitor liver cancer survivors for recurrence, reducing radiation exposure and contrast agent risks.
What could go wrong
This is a diagnostic accuracy study, not a treatment trial. The abbreviated MRI may not detect all recurrences, and results may not apply to all patient groups or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 455 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with more than two years without recurrence after curative treatment (surgery or local ablation) for HCC 2. Patients with no history of systemic treatment, radiation therapy, or trans-arterial chemoembolization for HCC 3. Older than 20 years of age 4. Eastern Cooperative Oncology Group performance status of 0-2 5. Patient is able to comply with scheduled visits, evaluation plans, and other study procedures 6. Patient is willing to provide written informed consent Exclusion Criteria: 1. Active or suspected cancer, or a history of malignancy where the risk of recurrence is equal or higher than 20% within 2 years. 2. Significant medical comorbidities in which survival is predicted to be less than 3 years 3. Estimated glomerular filtration rate \< 30 mL/min/1.73m² 4. Child-Pugh class C 5. Patient not eligible for applying LI-RADS criteria, such as Budd-Chiari Syndrome 6. Previous history of severe allergic reaction to iodine contrast medium 7. Precautions for MRI (cardiac pacemaker, severe claustrophobia that may interfere with protocol compliance). 8. Any other condition which, in the opinion of the Investigator, would make the patient unsuitable for enrollment or could interfere with completing the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Asan Medical Center

    RECRUITING

    Seoul, Songpa-gu , 88, Olympic-ro 43-gil, 05505, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.